It was shown that by the classical pathway of complement activation, it is possible to kill HIV-1 infected cells. It was found that fresh sera of Rabbit showed a dose dependent viral inactivating property against cell free HIV-1. Further in the present project, it is possible to elucidate the mechanism to understand the lack of activity of human serum against HIV-1. With the same idea, presently the work is ongoing to test a panel of HIV-2 sera for their ability to activate human complement by the classical pathway mediated Membrane Attack Complex System (MACS). Activation is being assessed by the C3-complement component deposition using anti C3 conjugated to FITC. Analysis of complement mediated cytolysis of infected cells using serum samples against recombinant HIV-1 env or core antigens speculates that env gp160/120 and gag p24 acts as target antigens for antibody and complement mediated cytolysis.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BP003005-03
Application #
5200826
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Bureau of Health Planning and Resources Development
Department
Type
DUNS #
City
State
Country
United States
Zip Code